The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Overcoming CAR-T resistance in CLL: combining with ibrutinib
Tanya Siddiqi, MD, City of Hope National Medical Center, Duarte, CA, discusses CAR-T resistance in chronic lymphocytic leukemia (CLL). She mentions the potential combination of CAR T-cells with ibrutinib to prevent resistance, which is being trialed in the TRANSCEND-CLL-004 study (NCT03331198). This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bristol Myers Squibb.
